- Home
- VRAR vs AXDX Comparison
VRAR vs AXDX Comparison
Compare VRAR & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- AXDX
- Stock Information
- Founded
- VRAR 2016
- AXDX 1982
- Country
- VRAR United States
- AXDX United States
- Employees
- VRAR N/A
- AXDX N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- VRAR Technology
- AXDX Industrials
- Exchange
- VRAR Nasdaq
- AXDX Nasdaq
- Market Cap
- VRAR 26.9M
- AXDX 27.0M
- IPO Year
- VRAR 2021
- AXDX 1996
- Fundamental
- Price
- VRAR $1.20
- AXDX $0.70
- Analyst Decision
- VRAR Strong Buy
- AXDX Hold
- Analyst Count
- VRAR 1
- AXDX 1
- Target Price
- VRAR $4.67
- AXDX $1.00
- AVG Volume (30 Days)
- VRAR 149.9K
- AXDX 48.9K
- Earning Date
- VRAR 05-14-2025
- AXDX 03-21-2025
- Dividend Yield
- VRAR N/A
- AXDX N/A
- EPS Growth
- VRAR N/A
- AXDX N/A
- EPS
- VRAR N/A
- AXDX N/A
- Revenue
- VRAR $9,230,197.00
- AXDX $11,698,000.00
- Revenue This Year
- VRAR $39.02
- AXDX $7.25
- Revenue Next Year
- VRAR N/A
- AXDX N/A
- P/E Ratio
- VRAR N/A
- AXDX N/A
- Revenue Growth
- VRAR N/A
- AXDX N/A
- 52 Week Low
- VRAR $0.50
- AXDX $0.69
- 52 Week High
- VRAR $7.00
- AXDX $2.09
- Technical
- Relative Strength Index (RSI)
- VRAR 42.23
- AXDX 22.53
- Support Level
- VRAR $1.10
- AXDX $0.69
- Resistance Level
- VRAR $1.33
- AXDX $1.09
- Average True Range (ATR)
- VRAR 0.11
- AXDX 0.10
- MACD
- VRAR 0.01
- AXDX -0.04
- Stochastic Oscillator
- VRAR 29.41
- AXDX 1.82
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.